VTRO (Vitro Biopharma) LT-Debt-to-Total-Asset: 0.35 (As of Oct. 2022)


What is Vitro Biopharma LT-Debt-to-Total-Asset?

Vitro Biopharma VTRO LT-Debt-to-Total-Asset is 0.35 as of Oct. 2022. The stock has 6 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Vitro Biopharma's long-term debt to total assests ratio for the quarter that ended in Oct. 2022 was 0.35.

Vitro Biopharma's long-term debt to total assets ratio increased from Oct. 2014 (0.00) to Oct. 2022 (0.35). It may suggest that Vitro Biopharma is progressively becoming more dependent on debt to grow their business.

Vitro Biopharma  (AMEX:VTRO) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Vitro Biopharma LT-Debt-to-Total-Asset Related Terms

Vitro Biopharma LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Vitro Biopharma's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vitro Biopharma LT-Debt-to-Total-Asset Chart

Vitro Biopharma Annual Data
Trend Oct09 Oct10 Oct11 Oct12 Oct13 Oct14 Oct15 Oct17 Oct21 Oct22
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.03 1.65 0.55 0.35

Vitro Biopharma Quarterly Data
Oct00 Oct01 Oct02 Oct03 Oct04 Oct05 Oct06 Oct07 Oct08 Oct09 Oct10 Oct11 Oct12 Oct13 Oct14 Oct15 Oct17 Oct21 Oct22
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.03 1.65 0.55 0.35

Vitro Biopharma LT-Debt-to-Total-Asset Calculation

Vitro Biopharma's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Oct. 2022 is calculated as

LT Debt to Total Assets (A: Oct. 2022 )=Long-Term Debt & Capital Lease Obligation (A: Oct. 2022 )/Total Assets (A: Oct. 2022 )
=2.976/8.574
=0.35

Vitro Biopharma's Long-Term Debt to Total Asset Ratio for the quarter that ended in Oct. 2022 is calculated as

LT Debt to Total Assets (Q: Oct. 2022 )=Long-Term Debt & Capital Lease Obligation (Q: Oct. 2022 )/Total Assets (Q: Oct. 2022 )
=2.976/8.574
=0.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.35 mean?
Vitro Biopharma (VTRO) has a LT-Debt-to-Total-Asset of 0.35 as of Oct. 2022. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Vitro Biopharma and its competitors.
Is Vitro Biopharma's LT-Debt-to-Total-Asset too high?
Vitro Biopharma's current LT-Debt-to-Total-Asset is 0.35.
How does Vitro Biopharma's LT-Debt-to-Total-Asset compare to ?
Vitro Biopharma's LT-Debt-to-Total-Asset of 0.35 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Vitro Biopharma and its competitors. Vitro Biopharma's current LT-Debt-to-Total-Asset is 0.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitro Biopharma stock overvalued right now?
Vitro Biopharma (VTRO) has a current LT-Debt-to-Total-Asset of 0.35. The current LT-Debt-to-Total-Asset is 0.35. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Vitro Biopharma (VTRO), the current LT-Debt-to-Total-Asset is 0.35 as of Oct. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vitro Biopharma Business Description

Comparable Companies
Address 4621 Technology Drive, Golden, CO, USA, 80403
Vitro Diagnostics Inc is a US-based company, which is dedicated to providing high-quality commercialized cell lines, media, and stem cell technology for applications in stem cell research, drug discovery, and therapies. In addition, it also provides tools for clinical development focused on Mesenchymal Stem Cells (MSCs). Further, it offers cancer-associated fibroblasts (CAFs), which are used in the discovery of a new type of CAFs present in pancreatic cancer tumors, called pancreatic stellate cells. Geographically business activities are functioned through the region of United States.